Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theratechnologies Inc T.TH

Alternate Symbol(s):  THTX

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.


TSX:TH - Post by User

Bullboard Posts
Comment by juniper88on Dec 04, 2019 4:24pm
223 Views
Post# 30422440

RE:RE:GLMD up another 13% this morning

RE:RE:GLMD up another 13% this morningWell at some point the price must we low enough for someone large to take a  position.  Right now THTX is trading at about 3.5 times sales.  Is Thera such a scourge that no one will touch it no matter the price?  Average sales to price ratio is just about 7.  So Thera is only half of that.  And at what point will insiders decide this is to cheap to pass up?  Back when Thera bought back the rights to Egrifta and the PPS was .35 cents I took out a large piece from my PLOC and bought as many TH shares as I could.  I thought at the time that it would go up to 2.5 to 3.0 within a couple of years.  Aren't we in a similar situation here?  Palinc made an interesting point about Dubuc not to long ago.  He doesn't own that much, in fact considerably less than many of us here.  So, Mr. Dubuc, I challenge you; if you believe in the story you are trying to sell to potential investors then can you please buy considerably more than a 1,000 shares next time?  Even if you have to borrow the money from your PLOC.


qwerty22 wrote: I think we all now recognize we are in a hole when it comes to market interest. Getting out of that hole is a process and this report is one step in that process.

We can spend our time wondering how we got in the hole, spend our time describing the fact that we are in that hole, spend our time identifying the route out of the hole and spend our time identifying steps the company are going through to actually get out of that hole. All of those probably have some use, ignoring any of them would probably be wrong.

Mr Nash's report and the market response probably show us we are in the hole and also the ultimate route out of the hole.



palinc2000 wrote: I guess there are no tax sellers for GLMD




Bullboard Posts